All In Biotech

Drug Trial Radar · NCT06125327

SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)

A Randomized, Double-blind, Placebo-controlled Phase II/III Trial Evaluating the Efficacy and Safety of Sufenidone (SC1011) Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF).

Last checked: Nov 19, 2026Latest source record: Nov 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 210 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

210

Planned (sponsor's estimate)

Start

Jun 6, 2023

Primary completion

Dec 31, 2026

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Guangzhou JOYO Pharma Co., LtdIndustry
Sponsor type
Industry
First posted
Nov 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluating Sufenidone (SC1011) in IPF patients for efficacy and safety. Includes screening, treatment, and follow-up, with FVC decline and health checks.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • SC1011Drug

    Patients receive the dose of SC1011 tablets orally twice daily (b.i.d) for 52 weeks.

  • Placebo comparatorDrug

    Patients receive the dose of placebo orally twice daily (b.i.d) for 52 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 WeeksTime frame: Primary Outcome measures will be assessed at baseline and again at 52 weeks.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.